**Core tip:** We present a rare case of adenosquamous pancreatic carcinoma (ASPC) arising in an intraductal papillar mucinous neoplasm in a *CDKN2A* germline mutation carrier from a kindred with familial atypical multiple mole melanoma. The case is an accelerated model of the adenoma-carcinoma sequence in pancreatic carcinogenesis. We discuss the differential diagnoses of squamous lesions in the pancreas and review the clinical and morphological features of ASPC.

INTRODUCTION
============

Ductal adenocarcinoma is the most frequent malignant tumour of the pancreas, and with a life expectancy of 5% at 5 years, the prognosis has not improved in the last 20 years\[[@B1]\]. Surgical excision, the only potentially curative treatment, yields a 20% chance of 5-year survival\[[@B1]\]. Unfortunately, only 15%-20% of patients are candidates for surgical resection due to distant metastases or locally advanced disease at diagnosis\[[@B1]\]. Hence, much effort should be focused in recognizing premalignant lesions or early invasive carcinomas. Pancreatic cancer screening risks outweigh benefits in the general population, but it might benefit individuals at high risk of pancreatic cancer\[[@B2]\]. However, only 10% of the pancreatic cancers are considered to be caused by inherited germline mutations, sporadically occurring mutations being responsible for the vast majority\[[@B3]\]. Pancreatic adenosquamous carcinoma is a rare variant with even worse prognosis than adenocarcinoma with some distinct clinical, imaging and pathological features\[[@B4],[@B5]\]. We present the case of a pancreatic cancer predisposing germinal mutation carrier who developed an adenosquamous carcinoma of the pancreas arising in an intraductal papillar mucinous neoplasm. The case illustrates the adenoma-carcinoma sequence in pancreatic cancer, probably accelerated due to the germline mutation.

CASE REPORT
===========

A 69-year-old woman attended the hospital with upper abdominal pain of growing intensity during two months. She had a cutaneous malignant melanoma resected in 1997 and was a carrier of a germline mutation in *CDKN2A* at codon 59 (GTG\>GGG) from a kindred with Familial Atypical Mole Melanoma (FAMMM). The computed tomography (CT) revealed a 30-mm solid-cystic mass in the body of the pancreas, with ill-defined borders, pancreatic tail atrophy, splenic vessels encasement and partial superior mesenteric artery and vein involvement (Figure [1A](#F1){ref-type="fig"}). The celiac trunk and branches were not involved. A CT performed 3 years previously due to a self-limited diffuse abdominal pain, resulted in no evident pancreatic lesion (Figure [1B](#F1){ref-type="fig"}). Radial and linear endoscopic ultrasonography (EUS) (Figure [2](#F2){ref-type="fig"}) confirmed the CT findings and the transgastric EUS guided fine needle aspiration (EUS-FNA) showed the presence of malignant cells with both glandular and squamous differentiation (Figure [3A](#F3){ref-type="fig"} and B). The multidisciplinary oncology board considered the tumour borderline for surgical resection, hence neoadjuvant chemotherapy with FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan and oxaliplatin) was indicated. After the neoadjuvant treatment, pain was relieved and CT showed reduction in the tumor size and no superior mesenteric artery involvement, therefore the patient was considered for surgical treatment. Partial pancreatectomy including the body and the tail together with splenectomy was performed without complications. In the surgical specimen, the pathological study of the solid-cystic mass (Figure [3C](#F3){ref-type="fig"} and D) showed an intraductal papillary mucinous neoplasm (IPMN) in connection with adenocarcinoma and squamous cell carcinoma components (Figure [4](#F4){ref-type="fig"}). Squamous metaplasia was also observed. The squamous carcinoma represented one third of the whole malignant component, thus a final diagnosis of pancreatic adenosquamous carcinoma probably arising in an IPMN was rendered. The immunohistochemical study showed CK (34βE12/p63, CEA and CK 5/6 strong positivity in the squamous component. CK 7 and MUC5A revealed strong positivity in the adenocarcinoma area (Figure [5A](#F5){ref-type="fig"}-C). p53 and EMA were strongly positive in both components (Figure [5D](#F5){ref-type="fig"}). Ki-67 index was 25%. The retroperitoneal surgical margin was affected, and 10 out of 27 lymph nodes were metastatic, one of them located between cava and aorta. The final pathological stage was ypT3N1M1. Five months after surgery, the patient is currently ongoing maintenance chemotherapy.

![Computed tomography image. A: Computed tomography (CT) image of the solid-cystic pancreatic mass with distal atrophy of the pancreas and pancreatic duct dilatation; B: CT three years before in which no pancreatic lesions were present.](WJGO-9-390-g001){#F1}

![Endoscopic ultrasonography image. A: Radial endoscopic ultrasonography (EUS) view of the mass; B: Lineal guided EUS fine needle aspiration of the solid component of the mass.](WJGO-9-390-g002){#F2}

![Endoscopic ultrasonography fine needle aspiration biopsies and surgical specimen. A and B: Positive cytology from the pancreatic mass (adenocarcinoma with a significant keratinizing component suggestive of adenosquamous carcinoma), Papanicolaou staining 20 × and 40 ×, respectively; C and D: A solid-cystic pancreatic mass (gross pathology).](WJGO-9-390-g003){#F3}

![Microscopic pathology of the surgical specimen. A: Intraductal papillary mucinous neoplasm with adenocarcinoma component, hematoxylin and eosin (H and E) 10 ×; B-D: Squamous metaplasia and evident infiltrative squamous carcinoma, H and E 10 ×, 20 × and 40 ×, respectively; E: Adenocarcinoma with perineural invasion, alcian blue 20 ×; F: Peripancreatic lymph node metastasis (adenocarcinoma component), H and E 20 ×.](WJGO-9-390-g004){#F4}

![Immunohistochemical study in the surgical specimen. A: CK5/6 strong positivity in squamous component (metaplasia and carcinoma), × 20; B: Strong nuclear p63 immunopositivity in the invasive squamous carcinoma. The adenocarcinoma area display poor p63 nuclear positivity, × 20; C: MUC5a negativity in the squamous carcinoma component and strong positive in ductal epithelial cells, × 20; D: MUC1/EMA positivity in the squamous metaplasic component, × 20.](WJGO-9-390-g005){#F5}

DISCUSSION
==========

Adenosquamous carcinomas may appear in various locations in the body (gastrointestinal tract\[[@B6],[@B7]\] female reproductive organs\[[@B8]\], lung, bladder). Adenosquamous pancreatic carcinoma (ASPC) is rare, accounting for less than 5% of all pancreatic carcinomas in the largest series\[[@B4]\]. Areas of squamous differentiation are often seen in a pancreatic ductal adenocarcinoma (PDA), but the diagnosis of ASPC is conventionally accepted only if the squamous component is present in at least 30% of the total volume of the tumour. Exclusively squamous carcinomas of the pancreas are exceptional; moreover, they are usually regarded as metastases from a primary squamous carcinoma. ASPC symptoms are basically the same as PDA's (mainly abdominal or back pain, but also jaundice, weight loss or diabetes depending on its relation with the biliary tract and the grade of exocrine and endocrine impairment caused). It may be seen more frequently in the head of the pancreas, but ASPC presents less likely in the head and more commonly in the body or tail than PDA\[[@B4]\]. It is slightly predominant in white males, around the seventh decade of life\[[@B4]\]. Respecting size, ASPC is usually bigger than PDA. The squamous component usually locates in the periphery of the lesion, whilst adenocarcinoma lays in the center. Extensive necrotic areas are more common in ASPC. Poor differentiation grade is frequent\[[@B4],[@B5]\], and tends to grow perineurally. In the same way, vascular and lymph nodes involvement is frequently seen\[[@B5]\]. Rhabdoid components\[[@B9]\], osteoclast-like and pleomorphic giant cells, and acantholisis\[[@B10]\] have been described in some cases. Immunohistochemical (IHC) analysis show positivity for keratins (AE1/E3, CK1, CK5/6, CK7, and less frequently Cam 5.2 and CK20)\[[@B11]\], p63 (which may be helpful in identifying squamous differentiation in cases with acantholysis), overexpression of EGFR, and reduced or loss of E-cadherin expression\[[@B12]\]. p16 and Dpc4 expression are usually lost or reduced and nuclear p53\[[@B12]\], CA 19.9 and CEA are usually positive\[[@B12]\] similar to PDA. One study\[[@B13]\] used an IHC commercial assay\[[@B14]\] of molecular markers which are implicated in anti-tumor drug performance, showing TOPO2A, MRP1, BCRP and MGMT overexpression. There is not a definitive sign of ASPC in imaging tests, but some studies remark that it is frequently round or has a lobulated shape\[[@B15]\] with ill-defined borders\[[@B16]\], and characteristically demonstrates central necrotic areas\[[@B15]\]. It usually displays peripheral contrast enhancement in the arterial phase, which persists in the venous phase\[[@B17]\], and thrombus in the portal vein system is often present\[[@B15]\]. Opposite to PDA, lack of distal glandular atrophy and only mild pancreatic ductal dilatation\[[@B16]\] have been noted. Not surprisingly, in view of the aggressive morphologic features, prognosis is even poorer than PDA's: In a large population based study comparing 415 cases of ASPC and 45693 of PDA, 2-year survival after surgery was 29% in ASPC patients and 36% in the PDA group (*P* \< 0.0001)\[[@B4]\]. A matched case control study yielded a significantly worse median overall survival of 8.38 mo in ASPC patients compared with 15.75 mo in PDA patients (HR = 1.94; 95%CI: 1.07-3.51; *P* = 0.026)\[[@B18]\].

The etiology of the ASPC is unknown, but there are three hypotheses that try to explain the development of ASPC: (1) Squamous carcinoma metaplasia may be a consequence of metaplastic changes due to the microenvironmental conditions in the ductal lumen obstructed by an already existent PDA; (2) areas of squamous carcinoma might be present since the first steps of carcinogenesis originated at the same time that the adenocarcinoma line from a common tumor stem cell; and (3) two concomitant carcinomas (squamous and adenocarcinoma) collide and merge forming one tumor mass. There are no studies that demonstrate which, if any, is correct, but some studies find the same KRAS mutation in both tumor lines\[[@B12]\] suggesting a common origin, thus making the collision hypothesis less likely.

The molecular alterations in ASPC are similar to PDA\[[@B12]\], being the loss of p16 (the protein coded by the gene *CDKN2A*) a common event in the early steps of pancreatic carcinogenesis. Loss of p16 may be caused by genetic mutations or gene silencing due to epigenetic changes. Our patient, being a carrier of a germline mutation in *CDKN2A*, had a predisposition to pancreatic cancer. As a fact, it has been estimated that carriers of a germline *CDKN2A* mutation in kindreds with FAMMM, have a 38-fold higher risk of pancreatic cancer than the general population\[[@B3]\]. Nevertheless, many other genetic, epigenetic or environmental factors and interactions among them must influence, as not all the families with *CDKN2A* mutations have a familial history of pancreatic cancer\[[@B19]\]. There are some scientific societies\[[@B20]-[@B22]\] that have reached some consensus in screening special populations with markedly increased risk of pancreatic cancer, mainly with EUS or MRI. Notwithstanding this, there are still knowledge gaps, lack of standardization in procedures, and differences in availability of resources that hinder the implementation in daily clinical practice, so that this patient was not following a pancreatic cancer screening program.

There are few reports of ASPC arising or associated with IPMN\[[@B23],[@B24]\]. IPMNs are premalignant lesions that are estimated to develop a carcinoma in 47% the main duct type, and in 17% the branch duct type\[[@B25]\]. It usually takes more than a decade to transform into a malignant invasive lesion, for those who eventually do\[[@B25]\]. Our patient had an abdominal CT three years before, in which no lesion was apparent in the pancreas. It could be argued that a lesion of less than 2 cm may have been overlooked; even if this was case, the sequence from premalignant to malignant was clearly accelerated, most probably due to the *CDKN2A* mutation.

The EUS-guided samples in our case showed plenty squamous component, not only in the cell aspirate but also in the cellular block, together with adenocarcinoma, therefore a diagnosis of ASPC was proposed. Preoperative diagnosis of ASPC is difficult: the finding of squamous component in the cytology should be interpreted cautiously, as it could represent contamination\[[@B26]\]. Furthermore, even if the specimen allows architectural study and thus contamination is likely ruled out, it is not possible to determine the proportion of squamous carcinoma in the whole malignant mass with the biopsy sampling. Hence, the preoperative diagnosis of ASPC may be suggested, but not definitive. The differential diagnosis when squamous component is found in a pancreatic neoplasia also includes ductal squamous metaplasia, mucoepidermoid carcinoma (which is characterized by the presence of squamoid intermediate cells and the absence of individual cell keratinization and keratin pearls) and pancreatoblastoma, which is rarely found in adults. In addition, in a patient with a previous history of malignant melanoma the possibility of de-differentiated melanoma with adenocarcinoma-like component should be also excluded\[[@B27]\].

In summary, this case illustrates the accelerated carcinogenesis in a genetically predisposed patient, with the premalignant ground (IPMN) and a rare malignant variant (ASPC), all together in one lesion. The imaging studies (CT) and especially EUS may help to detect this rare entity, although the definitive diagnosis requires surgical resection. Currently there is not a specific strategy for ASPC, but the advances in the molecular profiling and the new targeted therapies might change its management.
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COMMENTS
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Case characteristics
--------------------

A 69-year-old woman with antecedents of familial melanoma and *CDKN2A* mutation carrier presented with a two months of abdominal pain.

Clinical diagnosis
------------------

The physical exam was normal.

Differential diagnosis
----------------------

Although the abdominal pain was unspecific, the personal, familial and genetic antecedents lead to the suspicion of pancreatic carcinoma. The relevant differential diagnosis is mainly pathological. When squamous component is found in a pancreatic tumor, ductal squamous metaplasia, adenosquamous carcinoma, mucoepidermoid carcinoma, pancreatoblastoma, and metastasis of a primary squamous carcinoma or a de-differentiated melanoma with adenocarcinoma -like component, should be considered.

Laboratory diagnosis
--------------------

All labs, including CA19.9 were within normal limits.

Imaging diagnosis
-----------------

The computed tomography and endoscopic ultrasonography revealed a 30-mm solid-cystic mass in the body of the pancreas, with ill-defined borders, pancreatic tail atrophy, splenic vessels encasement and partial superior mesenteric artery and vein involvement.

Pathological diagnosis
----------------------

Pancreatic adenosquamous carcinoma in an intraductal papillary mucinous neoplasm.

Treatment
---------

Neoadjuvant chemotherapy (FOLFIRINOX) and partial pancreatectomy followed by adjuvant chemotherapy.

Related reports
---------------

Adenosquamous pancreatic carcinomas (ASPCs) are unfrequent have worse prognosis than pancreatic adenocarcinoma, and have rarely been described in a intraductal papillar mucinous neoplasm.

Term explanation
----------------

ASPC is a rare variant of pancreatic adenocarcinoma, characterized by the presence of squamous component in at least 30% of the tumoral mass. Intraductal papillary mucinous neoplasms (IPMN) are premalignant pancreatic cystic lesions which may need surgical resection. Cycline dependant kinase inhibitor 2A gene (*CDKN2A)* is a tumor suppressor gene that codes p16 or CDKN2A protein; mutations in this gene has been related to melanoma and pancreatic carcinoma, but also to head and neck, breast and lung cancers. Familial Atypical Mole Melanoma (FAMMM) includes families with a high tendency to develop malignant melanoma. Some of this families carry inherited mutations in *CDKN2A*.

Experiences and lessons
-----------------------

ASPC is a rare variant of pancreatic carcinoma and may develop in intrapapillary mucinous neoplasms as the usual pancreatic adenocarcinoma. *CDKN2A* germinal mutation carriers bear a high risk of pancreatic carcinoma. Although evidence supporting pancreatic cancer screening is limited, the indication of a surveillance strategy might be discussed with the patient.

Peer-review
-----------

The authors report a rare case of ASPC arising in a FAMMM patient who is a carrier of *CDKN2A* germline mutation. Although it is well know that FAMMM patient has a high risk of occurring pancreatic carcinoma, ASPC arising in a background of IPMN has rarely been reported. Therefore the paper may enrich our knowledge on FAMMM associated pancreatic tumor.
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